Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gabapentin + buprenorphine is a combination of two pharmaceutical drugs, each with distinct mechanisms of action. Gabapentin is an anticonvulsant and neuropathic pain agent that modulates the activity of voltage-gated calcium channels in the central nervous system, thereby reducing neuronal excitability and neurotransmitter release. It is primarily used for epilepsy, neuropathic pain, and restless leg syndrome[6][10]. Buprenorphine is a partial agonist at the mu-opioid receptor and antagonist at the kappa-opioid receptor; it acts as an opioid analgesic and is widely used in opioid use disorder (OUD) treatment to reduce withdrawal symptoms and cravings[8]. When combined, these drugs can potentiate each other's central nervous system depressant effects, increasing risks such as sedation, respiratory depression, impaired cognition, coma or death. This combination should only be used under close medical supervision due to significant interaction risks[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gabapentin + buprenorphine.